TABLE 1.

Effects of LY354740 on rat DOI-induced or anxiety models

Behavioral or Physiologic Test	Doses Tested (mg/kg, i.p., LY354740)	Observations Measured	Minimal Effective Dose (MED, mg/kg) of LY354740	Maximal or Near Maximal Effective LY354740 Dose	References
DOI (1.25 mg/kg, i.p.)-induced head twitchesa	0.3, 1, 3, 10	Suppression of DOI-induced head twitches	1	3	Gewirtz and Marek, 2000
DOI (5 mg/kg, i.p.)-induced BDNF mRNAa	0.1, 1, 10	Suppression of DOI-induced increase in BDNF mRNA (mPFC)	1	10	Gewirtz et al., 2002
DOI (3 mg/kg, i.p.)-induced c-fosb	1, 3, 10	Suppression of DOI-induced increase in c-fos immunoreactivity (mPFC)	3	3	Menezes et al., 2013
Vogel test or conflict drinking testb	0.25, 5, 1, 2, 4	Increase in punished responses while drinking under threat of shock	0.5	0.5	Kłodzińska et al., 1999
Lactate-induced panic physiologic responsec	0.3, 0.6	Suppression of lactate-induced increases in cardio/respiratory measures	0.3	0.6	Shekhar and Keim, 2000
Latate-induced panic behavioral responsec	0.3, 0.6	Attenuation of lactate-induced decreases in social interaction	0.6	0.6	Shekhar and Keim, 2000
Elevated plus mazeb	1, 3, 10	Increase in open arm time	10	10	Ferris et al., 2001
Fear-potentiated startleb	0.003, 0.03, 0.3, 3	Suppression of fear expression at doses having no effects on fear acquisition	0.3	3	Tizzano et al., 2002

BDNF, brain-derived neurotrophic factor; MED, minimal effective dose.

^aFifteen-min LY354740 pretreatment before DOI administration and beginning of behavioral session.

^bThirty-min LY354740 pretreatment before DOI pretreatment and/or beginning of behavioral session.

^cSixty-min LY354740 pretreatment before beginning of behavioral session.